An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a double-blind, placebo-controlled, randomised crossover proof of concept study

Although Alzheimer's disease affects around 800,000 people in the UK and costs almost £23 billion per year, currently licenced treatments only offer modest benefit at best. Seizures, which are more common in patients with Alzheimer's disease than age matched controls, may contribute to the...

Full description

Saved in:

Bibliographic Details
Published in:	Current controlled trials in cardiovascular medicine Vol. 22; no. 1; pp. 508 - 17
Main Authors:	Sen, Arjune, Akinola, Mary, Tai, Xin You, Symmonds, Mkael, Davis Jones, Gabriel, Mura, Sergio, Galloway, Joanne, Hallam, Angela, Chan, Jane Y C, Koychev, Ivan, Butler, Chris, Geddes, John, Van Der Putt, Rohan, Thompson, Sian, Manohar, Sanjay G, Frangou, Eleni, Love, Sharon, McShane, Rupert, Husain, Masud
Format:	Journal Article
Language:	English
Published:	England BioMed Central 31-07-2021 BMC
Subjects:	Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Alzheimer's disease Animals Anti-seizure medication Clinical trials Cognition Cognition & reasoning Convulsions & seizures Cross-Over Studies Dementia Double-Blind Method Double-blind studies Drug dosages Epilepsy Hospitals Humans Levetiracetam Levetiracetam - adverse effects Medicine Memory Mice Neurology Orthopedics Patients Pharmacists Proof of Concept Study Psychiatrists Quality of Life Randomised controlled trial Rheumatology Study Protocol United Kingdom > UK Pilot Epilepsy Randomised controlled trial Cognition Seizure Anti-seizure medication Dementia Levetiracetam Proof of concept
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!